Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab

Documenti analoghi

• Problematic Internet Use in Frontotemporal Dementia: A Case Series
  di: Daniele Urso, et al.
  Pubblicazione: (2026)
• Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
  di: Manuela Dicarlo, et al.
  Pubblicazione: (2026)
• Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
  di: Stefan J. Teipel, et al.
  Pubblicazione: (2024)
• post translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive decline
  di: Julia B. Libby, et al.
  Pubblicazione: (2025)
• Are lecanemab and donanemab disease‐modifying therapies?
  di: Timothy Daly, et al.
  Pubblicazione: (2024)